Amylyx Pharmaceuticals Inc (NAS:AMLX)

Q2 2026 Amylyx Pharmaceuticals Inc Earnings Call Transcript

Aug 6, 2026 / 12:00 PM GMT

Release Date Price: $24.19 (+10.71%)

Transcript 10-Q8-K

Key Points

Positve

Amylyx Pharmaceuticals Inc (AMLX) is on track for the pivotal Phase 3 LUCIDITY trial top-line data readout in late August or early September 2026, with the last participant having completed their final visit.
The company is actively preparing all sections of the NDA for a potential submission, with the 16-week double-blind data being the last major piece needed.
Commercial launch readiness for avexitide is progressing well, including the deployment of a field medical affairs team and the activation of a disease state education campaign ('Uncover the Mystery of Post Bariatric Hypoglycemia').
The company estimates a substantial US market opportunity of approximately 160,000 people living with post-bariatric hypoglycemia (PBH), supported by claims analysis and field insights.
A new specific ICD-10 code for PBH will be effective October 1, 2026, which is expected to increase disease recognition and aid in patient identification and tracking.
The broader pipeline is advancing, including positive week 96 data for AMX-0035 in Wolfram syndrome and progress in the Phase 1 trial for AMX-114 in ALS.
The company maintains a strong cash position of $250.8 million, providing a runway into 2028 to fund operations through key milestones, including a potential 2027 launch.
High intent to prescribe among endocrinologists for an approved PBH therapy has been demonstrated in market research, providing confidence in the commercial opportunity.

Negative

The company remains blinded to the LUCIDITY data and the database has not yet been locked, leaving uncertainty around the final results.
There is potential for the FDA to restrict the initial label to only Roux-en-Y gastric bypass patients, which could require an additional study to expand the indication to all PBH patients.
The company faces uncertainty regarding the placebo response rate in the Phase 3 trial, which is the first pivotal study in PBH and could impact the observed treatment effect.
SG&A expenses increased significantly (up 40% year-over-year) due to higher legal expenses, including a one-time legal charge, and investments in commercial initiatives.
The company is entering a quiet period after the call, which will limit communication and updates until the top-line data is released.
The early access program (EAP) is still in its early days, and the full demand and patient recruitment into the program have not yet been quantified.
The competitive landscape, while currently sparse, could evolve, and the company's long-term market position depends on the success of its first-in-class therapy and future pipeline candidates like AMX-318.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AMLX.OQ - Amylyx Pharmaceuticals, Inc.
Q2 2026 Amylyx Pharmaceuticals Inc Earnings Call
Aug 06, 2026 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning, my name is Carrie, and I will be your conference operator today.

At the time, I would like to welcome everyone to the Amalex Pharmaceuticals.

Quarter 2026 earnings conference call.

All participants will be in a in only mode.

After today's presentation, there will be an opportunity to ask questions.

To ask a question, please press star 1 on your telephone keypad.

To withdraw your question, please press star 1 again.

Please be advised that this call is being recorded at the company's request.

I would now like to turn my call over to Lindsay Allen, Vice President, Investor Relations and communications.

Please proceed.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.